<DOC>
	<DOCNO>NCT01925157</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug know LY3090106 healthy participant participant RA inadequate response methotrexate ( MTX ) . The study investigate body process study drug study drug affect body . The study last 3 month participant .</brief_summary>
	<brief_title>A Study LY3090106 Healthy Participants Participants With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion Criteria Healthy Participants : Males nonpregnant female age 18 65 year Body Mass Index ( BMI ) 18.5 32.0 kilogram per meter square ( kg/m^2 ) Inclusion Criteria Participants RA : Diagnosis least mildly active adultonset RA Positive anticitrullinated protein ( ACPA ) antibodies rheumatoid factor Regular use MTX least 12 week stable dose ( 10 25 mg/week ) least 4 week prior baseline American College Rheumatology ( ACR ) Functional Class I , II III Exclusion Criteria Healthy Participants : Have receive biologic agent within 3 month 5 halflives Have surgery within 12 week prior screen Known history human immunodeficiency virus ( HIV infection and/or positive human HIV antibody ) Have evidence , test positive , hepatitis C virus hepatitis B virus Have evidence active infection fever Have donate great 500 mL blood within 30 day prior screen Smoke great 10 cigarettes/day equivalent Have receive live vaccine within 1 month screen Have history allergy monoclonal antibody severe drug allergy Exclusion Criteria Participants RA : Have receive prior current treatment biologic RA therapy Have receive live vaccine 28 day prior screen intend receive live vaccine course study Hemoglobin &lt; 10 gram per deciliter ( g/dL ) , platelet count &lt; 100,000 cells/microliter ( uL ) , total white blood cell count &lt; 3000 cells/uL , neutrophil count &lt; 2000 cells/uL , lymphocyte count &lt; 500 cells/uL Aspartate transaminase ( AST ) &gt; 1.5 x upper limit normal range ( ULN ) , alanine transamine ( ALT ) &gt; 1.5 x ULN , creatinine &gt; 1.5 mg/dL ( 114 micromoles/liter [ uMol/L ] ) Treatment &gt; 10 mg/day unstable dose oral prednisone equivalent within 28 day baseline Have require increase dose new prescription narcotic within 28 day prior randomization Have receive parenteral corticosteroid within 28 day screen Treatment oral diseasemodifying antirheumatic drug ( DMARDs ) MTX within 4 week prior baseline Any neurological , psychiatric , vascular , system disorder could also affect evaluation disease activity assessment . Anemia chronic disease allow hemoglobin &gt; 10 g/dL Have rheumatic systemic autoimmune disease RA significant active systemic involvement secondary RA . Participants secondary Sjogren 's syndrome eligible . Uncontrolled arterial hypertension characterize confirm systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 90 mm Hg screen day study drug dose Poorly control diabetes define glycosylated hemoglobin ( HbA1c ) &gt; 8.0 % screen Known history human immunodeficiency virus ( HIV infection and/or positive human HIV antibody ) Have evidence , test positive , hepatitis C virus hepatitis B virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>